ADC Therapeutics adds Dr. Jean-Pierre Bizzari to its Board of Directors and announces CEO Ameet Mallik also joining the Board

– SWITZERLAND, Lausanne –  ADC Therapeutics SA (NYSE: ADCT) today announced the appointment of Dr. Jean-Pierre Bizzari (M.D.) to its Board of Directors, alongside CEO Ameet Mallik who has also joined the Board.

“Jean-Pierre is an exceptional addition to our Board. His integral role in the development and approval of leading cancer treatments across global markets will bring valuable perspective to ADC Therapeutics as we advance a robust pipeline of ADCs for the treatment of hematological cancers and solid tumors,” said Board Chairman, Ron Squarer.

About Dr. Jean-Pierre Bizzari

Dr. Jean-Pierre Bizzari is an internationally renowned oncologist with over 35 years of experience in oncology drug development. He was EVP and Group Head of Clinical Oncology Development at Celgene Corporation where he was responsible for clinical development and operations across the United States, Europe, and Asia/Japan. During his tenure at Celgene, he oversaw the development and approval of leading oncology products including REVLIMID (lenalidomide), VIDAZA (azacytidine), and ABRAXANE (nab-paclitaxel). Dr. Bizzari also served as VP, Clinical Oncology Development for Sanofi-Aventis (formerly Rhône-Poulenc, Rhône-Poulenc Rorer, and Aventis) where he oversaw the approval of ELOXATIN (oxaliplatin), TAXOTERE (docetaxel) and ELITEK (rasburicase).

Dr. Bizzari currently serves on the scientific advisory boards of France’s National Cancer Institute and the European Organisation for Research and Treatment of Cancer. He also serves on the scientific advisory boards and board of directors at numerous global pharmaceutical companies. Dr. Bizzari has received various industry honors and has authored hundreds of scientific articles and publications.

Dr. Bizzari received his medical degree from the University of Nice and has trained at the Pitié-Salpêtrière Hospital in Paris, the Ontario Institute for Cancer Research, and the McGill Rosalind and Morris Goodman Cancer Research Centre (formerly the McGill Cancer Center) in Montreal, Canada.

“With a proprietary ADC platform validated by the FDA approval of ZYNLONTA, a robust pipeline of solid tumor targets, and a global team committed to transforming patients’ lives, ADC Therapeutics is poised to build on its success,” said Dr. Bizzari. “I look forward to working with the Board to continue ADC Therapeutics’ positive momentum and make a meaningful difference for patients with difficult-to-treat cancers.”

About ADC Therapeutics

ADC Therapeutics is a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody-drug conjugates. The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

ADC Therapeutics’ CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large b-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents. Cami (camidanlumab tesirine) is being evaluated in a pivotal Phase 2 trial for relapsed or refractory Hodgkin lymphoma and a Phase 1b clinical trial for various advanced solid tumors. In addition to ZYNLONTA and Cami, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.

For more information: https://www.adctherapeutics.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.